New Clots, Ten Days After a Hip Replacement: Picking an Anticoagulant Around a Liver That Isn't Quite Right
His platelet count and the timeline both point straight at heparin-induced thrombocytopenia — but the drug most doctors reach for first clears through a liver that his own labs say isn't working the way it should.
G.T., a 66-year-old man who spent thirty-one years delivering mail on foot before retiring, underwent an elective right hip arthroplasty ten days ago and had been recovering on schedule — walking with a physical therapist twice daily, pain controlled, incision healing cleanly — until his platelet count, which had been climbing normally after the expected postoperative dip, suddenly fell from 210,000/µL to 95,000/µL over 48 hours, and a duplex ultrasound ordered for new calf swelling confirmed a below-knee deep vein thrombosis in the same leg. He had been on prophylactic-dose subcutaneous heparin since surgery, and the combination — a greater-than-50-percent platelet fall beginning between days five and ten, with a new thrombotic event rather than bleeding — gives him a high pretest probability on the 4Ts score of Lo and colleagues, the pretest tool the 2018 ASH heparin-induced thrombocytopenia guidelines are built around, and a heparin-PF4 antibody test sent this morning is pending.
Heparin was stopped immediately on suspicion alone, per standard practice that does not wait for antibody confirmation once the clinical picture is this consistent, and the team now needs a non-heparin parenteral anticoagulant to treat both his new clot and his ongoing thrombotic risk from the antibody itself. The complicating detail is his liver: a preoperative panel had already flagged mildly elevated transaminases and an INR of 1.3 — numbers small enough to be waved through as fatty liver before a routine hip replacement, and never confirmed as hepatic rather than incidental — but genuinely relevant now that the first-line non-heparin option in most HIT protocols, argatroban, is cleared almost entirely by the liver rather than the kidneys — the opposite clearance profile from what his workup would predict as more forgiving for him.
In consult, ninety minutes after heparin was stopped
His creatinine is normal and his renal function isn't in question at all, unlike his liver. I'd choose fondaparinux specifically to sidestep the hepatic clearance uncertainty entirely — there's no reason to gamble on how significant his liver flag actually is when a fully renally-cleared option is available and his kidneys are unambiguously fine.
I'd want us to be precise about what his liver flag actually shows before treating it as disqualifying for argatroban — mildly elevated transaminases and an INR of 1.3 is consistent with fatty liver disease, not confirmed clinically significant hepatic dysfunction. Argatroban has the largest HIT-specific trial base of any of the three options and the monitoring protocol every team here already knows well. I'm not ready to set that aside on an incidental, unconfirmed lab pattern.
Normal creatinine tells us his kidneys are fine — it says nothing about whether his liver clearance is actually impaired, which is the thing that would need to be established before dismissing the concern.
I think this doesn't have to be resolved as argatroban-versus-fondaparinux on an uncertain liver reading either way. Bivalirudin clears through both enzymatic degradation and renal elimination — it doesn't depend on either organ system being the sole pathway, which removes the entire question you're both debating rather than picking a side of it. Its HIT evidence base is smaller and drawn more from cardiac and PCI populations than orthopedic ones like him, and that's a real, named tradeoff, not a free win.
Given that tradeoff is honest and his platelet count needs treatment now, not after further hepatic workup, I'd start bivalirudin today with aPTT-based titration and revisit if his response doesn't track the way it should.
Agreed: bivalirudin started today with aPTT-based titration, hepatic function panel repeated to clarify his baseline abnormality, warfarin bridging deferred until his platelet count recovers above 150,000/µL per standard HIT transition practice.